BC
KPTI icon

Birchview Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Birchview Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Sell
42,952
-41,000
-49% -$356K 0.2% 56
2026
Q1 		$468K Buy
+83,952
New +$640K 0.27% 55
2025
Q4 		– Sell
-27,985
Closed -$183K – 76
2025
Q3 		$183K Hold
27,985
– – 0.14% 64
2025
Q2 		$121K Hold
27,985
– – 0.12% 64
2025
Q1 		$105K Sell
27,985
-4
-0% -$34 0.09% 62
2024
Q4 		$284K Sell
27,989
-3,333
-11% -$40.3K 0.23% 50
2024
Q3 		$390K Hold
31,322
– – 0.34% 35
2024
Q2 		$408K Hold
31,322
– – 0.38% 34
2024
Q1 		$709K Hold
31,322
– – 0.58% 29
2023
Q4 		$406K Sell
31,322
-6,800
-18% -$91.6K 0.32% 37
2023
Q3 		$766K Buy
38,122
+18,700
+96% +$420K 0.65% 26
2023
Q2 		$521K Hold
19,422
– – 0.39% 36
2023
Q1 		$1.13M Hold
19,422
– – 0.89% 18
2022
Q4 		$991K Buy
19,422
+1,467
+8% +$102K 0.7% 22
2022
Q3 		$1.47M Hold
17,955
– – 1.04% 20
2022
Q2 		$1.22M Hold
17,955
– – 0.88% 20
2022
Q1 		$1.99M Buy
17,955
+1,555
+9% +$194K 1.43% 13
2021
Q4 		$1.58M Hold
16,400
– – 1.02% 18
2021
Q3 		$1.43M Buy
16,400
+1,067
+7% +$111K 0.97% 19
2021
Q2 		$2.37M Hold
15,333
– – 1.42% 11
2021
Q1 		$2.42M Buy
15,333
+2,800
+22% +$590K 1.44% 13
2020
Q4 		$2.91M Buy
12,533
+1,333
+12% +$309K 1.68% 12
2020
Q3 		$2.45M Hold
11,200
– – 1.64% 10
2020
Q2 		$3.18M Buy
11,200
+1,333
+14% +$394K 1.92% 8
2020
Q1 		$2.84M Buy
9,867
+4,534
+85% +$1.25M 2.52% 7
2019
Q4 		$1.53M Buy
5,333
+666
+14% +$144K 1.12% 10
2019
Q3 		$673K Hold
4,667
– – 0.45% 22
2019
Q2 		$419K Hold
4,667
– – 0.25% 35
2019
Q1 		$409K Hold
4,667
– – 0.26% 35
2018
Q4 		$656K Buy
4,667
+1,334
+40% +$225K 0.62% 20
2018
Q3 		$852K Hold
3,333
– – 0.55% 20
2018
Q2 		$850K Buy
+3,333
New +$824K 0.58% 20

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Birchview Capital's KPTI Position: Q2 2026 in Review

Birchview Capital reduced its Karyopharm Therapeutics (KPTI) stake by 49% in Q2 2026, selling an estimated $356K and leaving 42,952 shares worth $420K. The position accounts for 0.2% of the portfolio, ranked #56.

Birchview Capital first reported a position in KPTI in Q2 2018 and has held it in 32 quarters since. The position peaked at $3.18M in Q2 2020. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Birchview Capital held 42,952 shares of Karyopharm Therapeutics worth $420K as of Q2 2026.
  • Birchview Capital sold 41,000 Karyopharm Therapeutics shares in Q2 2026, an estimated $356K.
  • Karyopharm Therapeutics made up 0.2% of Birchview Capital's portfolio in Q2 2026, its #56 holding.
  • Birchview Capital first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • Birchview Capital's Karyopharm Therapeutics position peaked at $3.18M in Q2 2020.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.